Workflow
甘李药业(603087.SH):2025年中报净利润为6.04亿元、较去年同期上涨101.96%

Core Insights - The company reported a total revenue of 2.067 billion yuan for the first half of 2025, marking an increase of 755.2 million yuan compared to the same period last year, achieving a 57.18% year-on-year growth [1] - The net profit attributable to shareholders reached 604 million yuan, an increase of 305 million yuan year-on-year, reflecting a 101.96% growth [1] - The net cash inflow from operating activities was 249 million yuan, up by 182 million yuan year-on-year, representing a 275.25% increase [1] Financial Performance - The latest debt-to-asset ratio stands at 7.68%, a decrease of 0.23 percentage points from the previous quarter and a reduction of 0.48 percentage points year-on-year [3] - The gross profit margin is reported at 76.25%, an increase of 2.80 percentage points compared to the same period last year [3] - The return on equity (ROE) is 5.51%, up by 2.78 percentage points year-on-year [3] - The diluted earnings per share (EPS) is 1.02 yuan, an increase of 0.51 yuan year-on-year, achieving a 100.00% growth [3] - The total asset turnover ratio is 0.17 times, an increase of 0.06 times year-on-year, reflecting a 55.54% growth [3] - The inventory turnover ratio is 0.45 times, up by 0.07 times year-on-year, representing a 17.45% increase [3] Shareholder Structure - The number of shareholders is reported at 77,300, with the top ten shareholders holding a total of 282 million shares, accounting for 46.92% of the total share capital [3] - The largest shareholder, Gan Zhongru, holds 34.21% of the shares [3] - Other notable shareholders include Beijing Xute Hongda Technology Co., Ltd. with 5.90% and Hong Kong Central Clearing Limited with 1.25% [3]